Xuanzhu Biopharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2018-09-05
- Employees
- 251
- Market Cap
- -
- Website
- http://www.xuanzhubio.com
Clinical Trials
21
Active:2
Completed:1
Trial Phases
3 Phases
Phase 1:15
Phase 2:2
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
Phase 1
15 (71.4%)Phase 3
4 (19.0%)Phase 2
2 (9.5%)A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
Phase 3
Not yet recruiting
- Conditions
- Reflux Esophagitis (RE)
- Interventions
- Drug: Anaprazole + Rabeprazole placeboDrug: Rabeprazole + Anaprazole placebo
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT07010107
- Locations
- 🇨🇳
Shanghai Changhai Hospital, Shanghai, Shanghai, China
A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in Human
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05836805
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou Universiy, Suzhou, Jiangsu, China
A Study of KM501 in Patients With Solid Tumors
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT05804864
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China
A Study of XZB-0004 in Patients With Solid Tumors
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT05772455
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of KM602 in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05766527
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found